OncoSec Medical, a company developing late-stage intratumoral DNA‑based cancer immunotherapies, has teamed up with Providence Cancer Institute, a part of Providence St. Joseph Health, to pursue a first-in-human Phase 1 clinical trial of its novel DNA‑encodable, investigational vaccine, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19.    CORVax12 consists of OncoSec’s existing product candidate, TAVO (interleukin-12 or “IL-12” plasmid), in combin...